TrialBMC cancer2022

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma.

R Mercieca-Bebber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.